PhRMA Exec VP Conafay resigns; committee of three company reps will guide lobbying effort in interim.
Executive Summary
PhRMA CAPITOL HILL EFFORT WILL BE OVERSEEN BY THREE COMPANY EXECS from the government affairs offices of member companies following the Dec. 13 resignation by association Exec VP Stephen Conafay. The heads of the D.C. offices of Warner-Lambert (Vincent LoVoi) and Bristol-Myers Squibb (Richard Thompson) and the director of public policy at Lilly in Indianapolis (Anne Nobles) have been assigned to maintain the association's lobbying efforts. The three representatives were chosen because they are the top federal government relations staff for the current chairman of the association (Warner-Lambert's Lodewijk de Vink), the upcoming chairman (BMS Chairman Charles Heimbold), and the treasurer and chairman for 1997-1998 (Lilly Exec VP Sidney Taurel).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth